Quadrant Biosciences Inc

by

minimum investment: $300.00

Syracuse, NY

World’s First Saliva Test for Autism – Available in Clinics Now

We translate cutting edge research into practical diagnostic solutions for some of the most crucial public health issues facing the world today. Specifically, we have been early pioneers in identifying and developing epigenetic biomarkers in saliva, focusing on non-coding RNA and the microbiome. In addition to recently launching the first ever epigenetic saliva test for autism, we are currently working on developing similar tests for Parkinson’s disease, concussion, and Anorexia nervosa.

Funding target: $50,000 – $15,000,000 by 9/6/2020

Regulation A: Equity (Priced Round)

Minimum investment: $300

Category: